MétaCan
Menu
Back to cohort
Record W2169344399 · doi:10.1038/bjc.2012.338

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

2012· article· en· W2169344399 on OpenAlexafffund
Gordon Wishart, Chris Bajdik, Ed Dicks, Elena Provenzano, Marjanka K. Schmidt, Mark E. Sherman, David Greenberg, Andrew R. Green, Karen A. Gelmon, V-M Kosma, Janet E. Olson, Matthias W. Beckmann, Robert Winqvist, Simon S. Cross, Gianluca Severi, David G. Huntsman, Katri Pylkäs, Ian O. Ellis, Torsten O. Nielsen, Graham G. Giles, Carl Blomqvist, Peter A. Fasching, Fergus J. Couch, Emad A. Rakha, William D. Foulkes, Fiona M. Blows, L.R. Bégin, Laura J. van’t Veer, Melissa C. Southey, Heli Nevanlinna, Angela Cox, Maggie C.U. Cheang, Laura Baglietto, Carlos Caldas, Montserrat García‐Closas, Paul D.P. Pharoah

Bibliographic record

VenueBritish Journal of Cancer · 2012
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsHôpital du Sacré-Cœur de MontréalMcGill UniversityUniversity of British ColumbiaBC Cancer Agency
FundersBC Cancer AgencyCancer Research UKAcademy of FinlandNational Institutes of HealthKuopion Yliopistollinen SairaalaBreast Cancer CampaignMichael Smith Health Research BCSusan G. KomenHelsingin ja Uudenmaan SairaanhoitopiiriNational Cancer InstituteItä-Suomen YliopistoKWF KankerbestrijdingNational Institute for Health and Care Research
KeywordsBreast cancerMedicineOncologyInternal medicineHazard ratioProportional hazards modelStage (stratigraphy)CancerAdjuvantConfidence interval

Abstract

fetched live from OpenAlex

BACKGROUND: Predict (www.predict.nhs.uk) is an online, breast cancer prognostication and treatment benefit tool. The aim of this study was to incorporate the prognostic effect of HER2 status in a new version (Predict+), and to compare its performance with the original Predict and Adjuvant!. METHODS: The prognostic effect of HER2 status was based on an analysis of data from 10 179 breast cancer patients from 14 studies in the Breast Cancer Association Consortium. The hazard ratio estimates were incorporated into Predict. The validation study was based on 1653 patients with early-stage invasive breast cancer identified from the British Columbia Breast Cancer Outcomes Unit. Predicted overall survival (OS) and breast cancer-specific survival (BCSS) for Predict+, Predict and Adjuvant! were compared with observed outcomes. RESULTS: All three models performed well for both OS and BCSS. Both Predict models provided better BCSS estimates than Adjuvant!. In the subset of patients with HER2-positive tumours, Predict+ performed substantially better than the other two models for both OS and BCSS. CONCLUSION: Predict+ is the first clinical breast cancer prognostication tool that includes tumour HER2 status. Use of the model might lead to more accurate absolute treatment benefit predictions for individual patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: Simulation or modeling
GenreCandidate signal: Methods · Consensus signal: none
Teacher disagreement score0.005
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.279
Teacher spread0.258 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations201
Published2012
Admission routes2
Has abstractyes

Explore more

Same venueBritish Journal of CancerSame topicBreast Cancer Treatment StudiesFrench-language works237,207